{"product_id":"biolegend-430102","title":"Biolegend, 430102, ELISA MAX™ Standard Set Human IFN-γ, 10plates","description":"\u003cp\u003ePlease contact our sales representative for bulk pricing quotations.  ELISA Development Systems Engineered for Sensitive, Precise and Reliable Serum and Plasma Cytokine Quantitation  BioLegend's ELISA Max™ Sets provide all the time-savings, convenience and performance of a high-end, commercial ELISA kit for a fraction of the price! BioLegend's ELISA Max™ Sets, in two appealing formats, address the need for sensitivity, accuracy, dependability, and versatility of an ELISA development system, while providing maximum cost effectiveness, value, and ease of use. Both the ELISA Max™ Set Standard and ELISA Max™ Set Deluxe are specifically engineered for accurate recovery and measurement of analytes in complex fluids, such as serum and plasma (as well as activated cell cultures) without any interference by confounding serum factors, such as heterophilic antibody or rheumatoid factor.\u003cbr\u003e\n10plates\u003cbr\u003e\nVerified Reactivity: Human\u003cbr\u003e\nReported Reactivity: Cynomolgus\u003cbr\u003e\nApplication: ELISA\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Manaster I, et al. 2008. J. Immunol. PubMed Peng J, et al. 2005. J. Immunother. 28:599. PubMed Zhou J, et al. 2014. PLoS One. 9:94075. PubMed Sautto GA, et al. 2015. Gut. PubMed\u003cbr\u003e\nProduct Citations: Sautto G, et al. 2015. Gut. . PubMed Kang CE, et al. 2022. Sci Rep. 12:19030. PubMed Yang L, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed Martin A, et al. 2022. Mol Cancer Ther. 21:1184. PubMed Xiao Q, et al. 2022. Sci Immunol. 7:eabl3995. PubMed Asano T, et al. 2022. J Clin Lipidol. 17:78. PubMed Gartshteyn Y, et al. 2023. Life Sci Alliance. 6: . PubMed Chen L, et al. 2021. Int J Mol Sci. 22:. PubMed Wang J, et al. 2020. Cell. 183:1264. PubMed Manaster I, et al. 2008. J Immunol. 181:1869. PubMed Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed Mahoney KM, et al. 2019. Cancer Immunol Immunother. 68:421. PubMed Hsiao CC, et al. 2022. STAR Protoc. 3:101422. PubMed Wu J, et al. 2022. Mol Pharmacol. 102:161. PubMed Sohail A, et al. 2022. PLoS Pathog. 18:e1010219. PubMed Zhou J, et al. 2014. PLoS One. 9:94075. PubMed Du Q, et al. 2018. J Immunol. 201:533. PubMed Saraiva DP, et al. 2020. Front Oncol. 1.488194444. PubMed Chabanon RM, et al. 2019. J Clin Invest. 129:1211. PubMed Landgraf KE, et al. 2020. Commun Biol. 0.330555556. PubMed Zischke J, et al. 2017. PLoS Pathogens. 13(6):e1006454. PubMed Liu X, et al. 2020. Ther Adv Med Oncol. 12:1758835920910347. PubMed Ivagnes A, et al. 2017. Oncoimmunology. 7:e1386826. PubMed Li G, et al. 2021. Gut Microbes. 13:1968257. PubMed\u003cbr\u003e\nStandard Range: 7.8-500 pg\/mL\u003cbr\u003e\nCell Sources: CD8+ and CD4+ T cells, NK cells\u003cbr\u003e\nCell Type: Tregs\u003cbr\u003e\nBiology Area: Immunology, Innate Immunity, Neuroinflammation, Neuroscience\u003cbr\u003e\nMolecular Family: Cytokines\/Chemokines\u003cbr\u003e\nGene ID: 3458\u003cbr\u003e\nUniProt: View information about IFN-gamma on UniProt.org\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: IFN-g ELISA Kit\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46864322560169,"sku":"430102","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/biolegend-430102","provider":"Iright","version":"1.0","type":"link"}